Aclaris Therapeutics
ACRS
100 hedge funds and large institutions have $536M invested in Aclaris Therapeutics in 2018 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 46 increasing their positions, 28 reducing their positions, and 15 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 28
6.55% more ownership
Funds ownership: 92.38% → 98.94% (+6.6%)
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
2% less funds holding
Funds holding: 102 → 100 (-2)
24% less capital invested
Capital invested by funds: $703M → $536M (-$168M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $254K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$15.9M |
| 2 |
DM
Deerfield Management
New York
|
+$10.9M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$6.59M |
| 4 |
D.E. Shaw & Co
New York
|
+$4.56M |
| 5 |
JP Morgan Chase
New York
|
+$3.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$12.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.35M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.28M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$1.91M |
| 5 |
BlackRock
New York
|
-$1.86M |
ACRS Hedge Fund Activity: Q1 2018 in Review
100 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2018, worth a combined $536M — down 24% from $703M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ACRS and 14 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 46 added.
The largest buyer was Citadel Advisors, adding an estimated $15.9M. The largest seller was Putnam Investments, cutting an estimated $12.4M.
- 100 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2018, down from 102 in Q4 2017.
- Funds reported $536M of Aclaris Therapeutics stock for Q1 2018, down 24% quarter-over-quarter.
- 14 funds opened new Aclaris Therapeutics positions in Q1 2018 and 15 closed out, a net change of -1 holder.
- The largest Aclaris Therapeutics buyer in Q1 2018 was Citadel Advisors, an estimated $15.9M added.
- The largest Aclaris Therapeutics seller in Q1 2018 was Putnam Investments, an estimated $12.4M sold.
Based on aggregated 13F filings for Q1 2018.